Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 35 | 2024 | 2265 | 4.040 |
Why?
|
Breast Neoplasms | 83 | 2024 | 20822 | 3.170 |
Why?
|
Neoplasms | 61 | 2024 | 21683 | 2.580 |
Why?
|
Informed Consent | 10 | 2022 | 995 | 1.730 |
Why?
|
Cytochrome P-450 CYP2D6 | 8 | 2016 | 106 | 1.650 |
Why?
|
Tamoxifen | 10 | 2016 | 981 | 1.190 |
Why?
|
Early Detection of Cancer | 6 | 2022 | 3086 | 1.080 |
Why?
|
Quality of Life | 30 | 2023 | 12804 | 1.070 |
Why?
|
Exercise Therapy | 10 | 2023 | 906 | 1.010 |
Why?
|
Health Care Costs | 11 | 2023 | 3209 | 0.970 |
Why?
|
Biological Specimen Banks | 2 | 2019 | 711 | 0.950 |
Why?
|
Clinical Trials as Topic | 15 | 2024 | 7913 | 0.890 |
Why?
|
Antineoplastic Agents, Hormonal | 14 | 2024 | 1524 | 0.850 |
Why?
|
Ethics Consultation | 1 | 2022 | 52 | 0.830 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2020 | 1004 | 0.780 |
Why?
|
Music | 1 | 2023 | 263 | 0.730 |
Why?
|
Medical Assistance | 2 | 2017 | 104 | 0.710 |
Why?
|
Biopsy | 11 | 2022 | 6756 | 0.680 |
Why?
|
Therapies, Investigational | 2 | 2010 | 112 | 0.660 |
Why?
|
Tissue Banks | 1 | 2019 | 184 | 0.640 |
Why?
|
Health Expenditures | 8 | 2021 | 2348 | 0.640 |
Why?
|
Chemotherapy, Adjuvant | 19 | 2024 | 3479 | 0.640 |
Why?
|
Cost of Illness | 8 | 2023 | 1859 | 0.640 |
Why?
|
Mastectomy, Segmental | 6 | 2020 | 956 | 0.630 |
Why?
|
Mass Screening | 5 | 2022 | 5255 | 0.630 |
Why?
|
Health Care Rationing | 3 | 2021 | 437 | 0.610 |
Why?
|
Humans | 173 | 2024 | 744343 | 0.600 |
Why?
|
Patients | 6 | 2021 | 900 | 0.590 |
Why?
|
Cost-Benefit Analysis | 10 | 2022 | 5391 | 0.560 |
Why?
|
Health Services Needs and Demand | 3 | 2020 | 1411 | 0.540 |
Why?
|
Exercise | 7 | 2021 | 5615 | 0.540 |
Why?
|
Drug Costs | 4 | 2019 | 1105 | 0.530 |
Why?
|
Health Knowledge, Attitudes, Practice | 8 | 2016 | 3923 | 0.510 |
Why?
|
Fear | 3 | 2021 | 1440 | 0.500 |
Why?
|
Survivors | 12 | 2023 | 2291 | 0.490 |
Why?
|
Female | 106 | 2024 | 380194 | 0.480 |
Why?
|
Patient Preference | 2 | 2019 | 890 | 0.480 |
Why?
|
Insurance, Health | 3 | 2017 | 2494 | 0.480 |
Why?
|
Nurse Practitioners | 1 | 2017 | 270 | 0.480 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13695 | 0.460 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 591 | 0.430 |
Why?
|
Pharmacogenetics | 2 | 2014 | 675 | 0.420 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2009 | 129 | 0.420 |
Why?
|
Biomedical Research | 7 | 2020 | 3309 | 0.410 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1049 | 0.410 |
Why?
|
Tissue Extracts | 1 | 2012 | 135 | 0.410 |
Why?
|
Practice Guidelines as Topic | 8 | 2019 | 7279 | 0.400 |
Why?
|
Physician-Patient Relations | 7 | 2021 | 3229 | 0.400 |
Why?
|
Attitude of Health Personnel | 7 | 2019 | 3843 | 0.400 |
Why?
|
Emotions | 2 | 2023 | 2661 | 0.400 |
Why?
|
Ethics, Medical | 3 | 2022 | 792 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9239 | 0.390 |
Why?
|
Genetic Research | 1 | 2012 | 174 | 0.390 |
Why?
|
Public Opinion | 1 | 2015 | 477 | 0.380 |
Why?
|
Patient Participation | 6 | 2019 | 1457 | 0.380 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2013 | 629 | 0.370 |
Why?
|
Mandatory Testing | 1 | 2010 | 23 | 0.370 |
Why?
|
Fertility | 6 | 2022 | 781 | 0.360 |
Why?
|
Private Sector | 1 | 2013 | 392 | 0.360 |
Why?
|
Drug Industry | 3 | 2017 | 746 | 0.360 |
Why?
|
Databases as Topic | 1 | 2012 | 475 | 0.360 |
Why?
|
Learning | 1 | 2019 | 1713 | 0.360 |
Why?
|
Decision Making | 6 | 2018 | 3887 | 0.350 |
Why?
|
Carcinoma | 2 | 2021 | 2375 | 0.340 |
Why?
|
Perception | 2 | 2015 | 1198 | 0.340 |
Why?
|
Health Behavior | 2 | 2019 | 2636 | 0.340 |
Why?
|
Off-Label Use | 1 | 2010 | 169 | 0.340 |
Why?
|
Receptor, erbB-2 | 8 | 2023 | 2416 | 0.330 |
Why?
|
Middle Aged | 58 | 2024 | 213383 | 0.330 |
Why?
|
Health Services Accessibility | 7 | 2020 | 5137 | 0.330 |
Why?
|
Mammography | 2 | 2017 | 2476 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2021 | 9959 | 0.330 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 681 | 0.330 |
Why?
|
Health Resources | 1 | 2014 | 911 | 0.310 |
Why?
|
Adult | 56 | 2023 | 214055 | 0.310 |
Why?
|
Urologic Neoplasms | 1 | 2012 | 318 | 0.310 |
Why?
|
Neoadjuvant Therapy | 6 | 2020 | 2728 | 0.300 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2012 | 941 | 0.290 |
Why?
|
Cross-Sectional Studies | 13 | 2021 | 25043 | 0.290 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 577 | 0.280 |
Why?
|
Aged | 44 | 2023 | 163280 | 0.280 |
Why?
|
Receptors, Estrogen | 5 | 2020 | 2187 | 0.270 |
Why?
|
Self Efficacy | 3 | 2015 | 616 | 0.270 |
Why?
|
Patient Acceptance of Health Care | 3 | 2018 | 3022 | 0.270 |
Why?
|
Quality of Health Care | 6 | 2018 | 4371 | 0.270 |
Why?
|
Epidemiologic Research Design | 1 | 2009 | 367 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 841 | 0.260 |
Why?
|
Attitude | 2 | 2020 | 776 | 0.250 |
Why?
|
Oxygen Consumption | 5 | 2023 | 1869 | 0.250 |
Why?
|
Adaptation, Psychological | 7 | 2022 | 2576 | 0.240 |
Why?
|
Information Dissemination | 1 | 2012 | 1099 | 0.230 |
Why?
|
Medical Errors | 1 | 2012 | 1297 | 0.230 |
Why?
|
Patient-Centered Care | 2 | 2022 | 1439 | 0.230 |
Why?
|
Patient Selection | 4 | 2014 | 4215 | 0.230 |
Why?
|
Cost Sharing | 2 | 2017 | 407 | 0.230 |
Why?
|
Societies, Medical | 7 | 2019 | 3743 | 0.220 |
Why?
|
Pilot Projects | 5 | 2023 | 8324 | 0.210 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 4328 | 0.210 |
Why?
|
Research Support as Topic | 1 | 2007 | 705 | 0.210 |
Why?
|
Employment | 1 | 2009 | 1132 | 0.210 |
Why?
|
Socioeconomic Factors | 9 | 2021 | 7785 | 0.210 |
Why?
|
Physicians | 5 | 2016 | 4567 | 0.200 |
Why?
|
Body Composition | 1 | 2011 | 2401 | 0.200 |
Why?
|
Life Style | 3 | 2021 | 3835 | 0.200 |
Why?
|
Mastectomy | 5 | 2021 | 1793 | 0.200 |
Why?
|
Receptors, Progesterone | 3 | 2021 | 1097 | 0.200 |
Why?
|
Prospective Studies | 20 | 2023 | 53288 | 0.190 |
Why?
|
Ethics Committees, Research | 1 | 2022 | 194 | 0.190 |
Why?
|
Medication Adherence | 7 | 2024 | 2063 | 0.190 |
Why?
|
Genotype | 9 | 2020 | 12951 | 0.190 |
Why?
|
Income | 4 | 2021 | 1913 | 0.190 |
Why?
|
BRCA2 Protein | 2 | 2022 | 794 | 0.180 |
Why?
|
Anxiety | 3 | 2023 | 4297 | 0.180 |
Why?
|
Data Collection | 4 | 2014 | 3341 | 0.180 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8642 | 0.180 |
Why?
|
Telemedicine | 3 | 2022 | 2872 | 0.180 |
Why?
|
United States | 21 | 2023 | 69872 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 11524 | 0.180 |
Why?
|
Publishing | 1 | 2007 | 833 | 0.170 |
Why?
|
Habits | 1 | 2020 | 139 | 0.170 |
Why?
|
Social Justice | 1 | 2024 | 456 | 0.170 |
Why?
|
Neoplasm Staging | 10 | 2022 | 11031 | 0.170 |
Why?
|
Aged, 80 and over | 22 | 2021 | 57776 | 0.170 |
Why?
|
Feasibility Studies | 4 | 2023 | 5078 | 0.170 |
Why?
|
Genomics | 4 | 2023 | 5720 | 0.160 |
Why?
|
Resource Allocation | 1 | 2021 | 341 | 0.160 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2020 | 255 | 0.160 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2020 | 1101 | 0.160 |
Why?
|
Health Status Disparities | 2 | 2012 | 1797 | 0.160 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1149 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.160 |
Why?
|
Menopause | 4 | 2017 | 1626 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 489 | 0.150 |
Why?
|
Nontherapeutic Human Experimentation | 1 | 2017 | 24 | 0.150 |
Why?
|
Healthcare Disparities | 5 | 2017 | 3158 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2021 | 1770 | 0.150 |
Why?
|
Medicare | 2 | 2015 | 6566 | 0.150 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2765 | 0.150 |
Why?
|
Palliative Care | 3 | 2020 | 3493 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2022 | 323 | 0.150 |
Why?
|
Organizational Policy | 1 | 2019 | 429 | 0.150 |
Why?
|
Male | 26 | 2021 | 350118 | 0.150 |
Why?
|
Aromatase Inhibitors | 3 | 2015 | 491 | 0.140 |
Why?
|
Patient Satisfaction | 4 | 2021 | 3396 | 0.140 |
Why?
|
Fatigue | 2 | 2022 | 1531 | 0.140 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 288 | 0.140 |
Why?
|
Treatment Outcome | 14 | 2021 | 63114 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 640 | 0.140 |
Why?
|
Communication | 5 | 2019 | 3749 | 0.140 |
Why?
|
Carcinoma, Ductal | 1 | 2016 | 101 | 0.140 |
Why?
|
Diphosphonates | 2 | 2012 | 623 | 0.140 |
Why?
|
Health Planning | 1 | 2017 | 238 | 0.140 |
Why?
|
Financial Support | 2 | 2013 | 115 | 0.130 |
Why?
|
Fasting | 1 | 2022 | 1593 | 0.130 |
Why?
|
Rural Population | 2 | 2017 | 2210 | 0.130 |
Why?
|
Prognosis | 8 | 2020 | 29063 | 0.130 |
Why?
|
Breast | 2 | 2022 | 1969 | 0.130 |
Why?
|
Delivery of Health Care | 4 | 2019 | 5319 | 0.130 |
Why?
|
Resilience, Psychological | 1 | 2022 | 676 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9438 | 0.120 |
Why?
|
Health Priorities | 1 | 2017 | 380 | 0.120 |
Why?
|
Focus Groups | 1 | 2019 | 1321 | 0.120 |
Why?
|
Social Support | 2 | 2022 | 2118 | 0.120 |
Why?
|
Stress, Psychological | 3 | 2022 | 4245 | 0.120 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2278 | 0.120 |
Why?
|
Age Factors | 7 | 2021 | 18370 | 0.120 |
Why?
|
Needs Assessment | 1 | 2020 | 1147 | 0.120 |
Why?
|
Organizational Affiliation | 1 | 2013 | 33 | 0.120 |
Why?
|
Reaction Time | 1 | 2019 | 2097 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 500 | 0.110 |
Why?
|
Young Adult | 12 | 2022 | 56430 | 0.110 |
Why?
|
Ethics Committees | 1 | 2012 | 54 | 0.110 |
Why?
|
Exercise Test | 3 | 2014 | 2074 | 0.100 |
Why?
|
Health Care Surveys | 2 | 2018 | 2453 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15519 | 0.100 |
Why?
|
Aftercare | 1 | 2018 | 866 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2017 | 853 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2459 | 0.100 |
Why?
|
North Carolina | 1 | 2012 | 315 | 0.100 |
Why?
|
Cost Savings | 2 | 2014 | 926 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3610 | 0.100 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2013 | 282 | 0.100 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2013 | 235 | 0.100 |
Why?
|
Skinfold Thickness | 1 | 2011 | 162 | 0.100 |
Why?
|
Culture | 1 | 2015 | 633 | 0.100 |
Why?
|
Tissue Donors | 1 | 2020 | 2240 | 0.100 |
Why?
|
Plethysmography | 1 | 2011 | 180 | 0.100 |
Why?
|
Cluster Analysis | 1 | 2018 | 2715 | 0.100 |
Why?
|
Ambulatory Care | 1 | 2021 | 2708 | 0.090 |
Why?
|
Disclosure | 2 | 2014 | 736 | 0.090 |
Why?
|
Choice Behavior | 1 | 2016 | 803 | 0.090 |
Why?
|
Research | 2 | 2010 | 1999 | 0.090 |
Why?
|
Awareness | 1 | 2014 | 640 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2109 | 0.090 |
Why?
|
Family | 1 | 2021 | 3147 | 0.090 |
Why?
|
Biotransformation | 1 | 2009 | 168 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1256 | 0.090 |
Why?
|
Mind-Body Therapies | 2 | 2023 | 247 | 0.090 |
Why?
|
Patient Advocacy | 1 | 2012 | 353 | 0.090 |
Why?
|
Marital Therapy | 1 | 2009 | 45 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1832 | 0.080 |
Why?
|
Carcinoma, Lobular | 1 | 2013 | 484 | 0.080 |
Why?
|
Educational Status | 1 | 2017 | 2540 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12245 | 0.080 |
Why?
|
Research Design | 3 | 2022 | 5987 | 0.080 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2242 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 512 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 631 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2012 | 780 | 0.080 |
Why?
|
Models, Economic | 2 | 2011 | 713 | 0.080 |
Why?
|
Complementary Therapies | 1 | 2012 | 486 | 0.080 |
Why?
|
Conflict of Interest | 1 | 2013 | 544 | 0.080 |
Why?
|
Risk Assessment | 8 | 2018 | 23338 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1209 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2014 | 555 | 0.080 |
Why?
|
Retrospective Studies | 7 | 2023 | 77449 | 0.080 |
Why?
|
Costs and Cost Analysis | 3 | 2018 | 1681 | 0.080 |
Why?
|
Electric Impedance | 1 | 2011 | 729 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2022 | 1000 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2010 | 601 | 0.070 |
Why?
|
Human Experimentation | 1 | 2007 | 127 | 0.070 |
Why?
|
Caregivers | 1 | 2018 | 2094 | 0.070 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1831 | 0.070 |
Why?
|
Logistic Models | 4 | 2017 | 13408 | 0.070 |
Why?
|
Vaccination | 2 | 2018 | 3278 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1206 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1956 | 0.070 |
Why?
|
Carmustine | 1 | 2005 | 137 | 0.070 |
Why?
|
Communicable Diseases | 1 | 2014 | 880 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2012 | 1530 | 0.070 |
Why?
|
Drug Evaluation | 1 | 2007 | 647 | 0.070 |
Why?
|
Patient Care Team | 2 | 2016 | 2531 | 0.070 |
Why?
|
Drug Approval | 1 | 2012 | 742 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39050 | 0.060 |
Why?
|
Health Surveys | 1 | 2015 | 4037 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3019 | 0.060 |
Why?
|
Survival Analysis | 2 | 2008 | 10252 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3218 | 0.060 |
Why?
|
Premenopause | 1 | 2009 | 1033 | 0.060 |
Why?
|
Guideline Adherence | 2 | 2012 | 2266 | 0.060 |
Why?
|
Consensus | 1 | 2014 | 2959 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7181 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2011 | 4933 | 0.060 |
Why?
|
Mutation | 4 | 2023 | 29786 | 0.060 |
Why?
|
Ovary | 1 | 2009 | 981 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2012 | 1023 | 0.060 |
Why?
|
Survival Rate | 4 | 2016 | 12788 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6933 | 0.060 |
Why?
|
Authorship | 1 | 2007 | 271 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1584 | 0.060 |
Why?
|
Cohort Studies | 5 | 2023 | 40561 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1511 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2021 | 5181 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3920 | 0.060 |
Why?
|
Walking | 1 | 2010 | 1180 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5535 | 0.060 |
Why?
|
Phenotype | 3 | 2020 | 16365 | 0.050 |
Why?
|
Probability | 1 | 2008 | 2505 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 383 | 0.050 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 2795 | 0.050 |
Why?
|
Patient Care | 1 | 2007 | 640 | 0.050 |
Why?
|
Postmenopause | 1 | 2010 | 2461 | 0.050 |
Why?
|
Adolescent | 7 | 2022 | 85781 | 0.050 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4851 | 0.050 |
Why?
|
Time Factors | 4 | 2020 | 40075 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 310 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 12 | 0.050 |
Why?
|
Reference Values | 1 | 2008 | 4982 | 0.050 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2124 | 0.050 |
Why?
|
Advisory Committees | 2 | 2016 | 775 | 0.050 |
Why?
|
Administration, Oral | 1 | 2008 | 3913 | 0.040 |
Why?
|
Risk Factors | 6 | 2021 | 72290 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 795 | 0.040 |
Why?
|
Cisplatin | 1 | 2005 | 1662 | 0.040 |
Why?
|
Pharmacies | 1 | 2021 | 150 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19905 | 0.040 |
Why?
|
Bipolar Disorder | 1 | 2016 | 5027 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 10900 | 0.040 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 284 | 0.040 |
Why?
|
Oxygen | 1 | 2010 | 4189 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 355 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 317 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2684 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 402 | 0.040 |
Why?
|
Lung | 1 | 2016 | 9856 | 0.040 |
Why?
|
Health Promotion | 1 | 2010 | 2205 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 643 | 0.040 |
Why?
|
Pregnancy | 4 | 2023 | 29144 | 0.040 |
Why?
|
Prescription Fees | 1 | 2018 | 146 | 0.040 |
Why?
|
Insurance Coverage | 2 | 2018 | 1901 | 0.040 |
Why?
|
Doxorubicin | 2 | 2013 | 2234 | 0.040 |
Why?
|
Anthracyclines | 1 | 2018 | 288 | 0.030 |
Why?
|
Immunotherapy | 1 | 2012 | 4445 | 0.030 |
Why?
|
Genetic Testing | 1 | 2009 | 3444 | 0.030 |
Why?
|
Heterozygote | 1 | 2022 | 2804 | 0.030 |
Why?
|
Body Image | 1 | 2020 | 610 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6364 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2052 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12354 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1063 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7799 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2902 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 692 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2014 | 50 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2013 | 21746 | 0.030 |
Why?
|
Odds Ratio | 2 | 2020 | 9849 | 0.030 |
Why?
|
Psychotherapy | 1 | 2023 | 1643 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1993 | 230 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 847 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10943 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 523 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1993 | 299 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12261 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2016 | 618 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 896 | 0.030 |
Why?
|
Placebos | 1 | 2017 | 1676 | 0.030 |
Why?
|
Depression | 2 | 2023 | 7766 | 0.030 |
Why?
|
Virus Diseases | 1 | 2018 | 711 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2016 | 781 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1788 | 0.030 |
Why?
|
Weight Gain | 1 | 2022 | 2292 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2020 | 6365 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2924 | 0.030 |
Why?
|
Lymphedema | 1 | 2018 | 534 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2004 | 3589 | 0.020 |
Why?
|
Mammaplasty | 1 | 2021 | 1204 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4669 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 561 | 0.020 |
Why?
|
Cost Control | 1 | 2013 | 624 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2018 | 1547 | 0.020 |
Why?
|
Health Policy | 2 | 2011 | 2661 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1915 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2622 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 13881 | 0.020 |
Why?
|
Comprehension | 1 | 2016 | 610 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 2879 | 0.020 |
Why?
|
Postoperative Care | 1 | 2017 | 1486 | 0.020 |
Why?
|
Cognition | 1 | 2007 | 6770 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2018 | 1401 | 0.020 |
Why?
|
Incidence | 1 | 2008 | 20947 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 13989 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15076 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2014 | 643 | 0.020 |
Why?
|
Health Services Misuse | 1 | 2011 | 243 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2948 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2488 | 0.020 |
Why?
|
Genes | 1 | 1993 | 1893 | 0.020 |
Why?
|
Sick Role | 1 | 2009 | 237 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1186 | 0.020 |
Why?
|
Developing Countries | 1 | 2021 | 2815 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2951 | 0.020 |
Why?
|
Physical Fitness | 1 | 2013 | 733 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1170 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2019 | 3474 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2013 | 770 | 0.020 |
Why?
|
Standard of Care | 1 | 2012 | 564 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
Beneficence | 1 | 2007 | 53 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1405 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2825 | 0.020 |
Why?
|
Child | 3 | 2022 | 77709 | 0.020 |
Why?
|
Pain | 1 | 2022 | 4986 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15165 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1993 | 1121 | 0.020 |
Why?
|
Cardiovascular System | 1 | 2014 | 832 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2703 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3670 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4751 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17446 | 0.020 |
Why?
|
Stroke Volume | 1 | 2018 | 5007 | 0.020 |
Why?
|
Europe | 1 | 2011 | 3339 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1889 | 0.010 |
Why?
|
Health Services Research | 1 | 2011 | 1836 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2016 | 3528 | 0.010 |
Why?
|
Education, Medical | 1 | 1995 | 1721 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2016 | 3748 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 25625 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 2635 | 0.010 |
Why?
|
Curriculum | 1 | 1995 | 3605 | 0.010 |
Why?
|
Goals | 1 | 2007 | 706 | 0.010 |
Why?
|
Alzheimer Disease | 2 | 1993 | 8037 | 0.010 |
Why?
|
Health Care Reform | 1 | 2011 | 1261 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2013 | 3086 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12959 | 0.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3658 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4456 | 0.010 |
Why?
|
Electrocardiography | 1 | 2014 | 6442 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3567 | 0.010 |
Why?
|
Motivation | 1 | 2009 | 1971 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 13033 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5221 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10262 | 0.010 |
Why?
|
Diet | 1 | 2014 | 7939 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9687 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13102 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1993 | 457 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1993 | 2421 | 0.000 |
Why?
|
Genetic Markers | 1 | 1993 | 2634 | 0.000 |
Why?
|
Pedigree | 1 | 1993 | 4644 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4740 | 0.000 |
Why?
|
Models, Biological | 1 | 1993 | 9583 | 0.000 |
Why?
|